Xalatan receives paediatric indication in Europe

Article

Pfizer has announced that Xalatan (latanoprost) has been approved by the European Commission for the reduction of elevated IOP in the treatment of paediatric patients.

Pfizer has announced that Xalatan (latanoprost) has been approved by the European Commission for the reduction of elevated IOP in the treatment of paediatric patients. This is the first time that a prostaglandin analogue has completed safety and efficacy trials in a paediatric population and has been indicated for use in patients aged 18 or younger in Europe.

The EU approval has been based on Phase III and Phase I studies that were contained in Pfizer's Paediatric Investigation Plan as agreed with the European Medicines Agency (EMA) in accordance with the EU Paediatrics Medicines Regulation. As a result of its compliance with these regulations Pfizer can and will apply for a six-month patent protection extension in European countries where it currently has a Supplementary Protection Certificate (SPC).

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.